Abstract: OBJECTIVE To analyze the different therapeutic effects of different formulations of recombinant human growth hormone on idiopathic short stature and the related factors before treatment. METHODS Retrospective analysis was performed on children aged 4-8 years who were diagnosed as idiopathic short stature at the Child Health Department of Sichuan Maternal and Child Health Care Hospital from January 2020 to December 2021 and treated with different formulation of recombinant human growth hormone. The changes of height growth value and growth factor levels of children in different groups during different treatment periods were compared. At the same time, Logistic regression analysis was carried out on the related factors affecting the effect of height growth before treatment. RESULTS There was no significant difference in height, IGF-1 and IGF-BP₃ growth between the two groups at each stage of treatment, except for the statistical difference in IGF-BP₃ increment at the third month of treatment(P<0.05); The age of treatment had an effect on the height growth outcome of children, and there was statistical significance(OR=0.258, 95%CI 0.109-0.609, P=0.002). The remaining factors had no obvious influence. CONCLUSION There is no difference in the therapeutic effect of different formulation of recombinant human growth hormone on idiopathic short stature. The age of beginning use is the main factor that affects the effect of using growth hormone.